Literature DB >> 10602670

Antibiotics and Clostridium difficile.

J Freeman1, M H Wilcox.   

Abstract

Clostridium difficile is now established as a major nosocomial pathogen. C. difficile infection is seen almost exclusively as a complication of antibiotic therapy, and is particularly associated with clindamycin and third-generation cephalosporins. Depletion of the indigenous gut microflora by antibiotic therapy has long been established as a major factor in the disease. However, the direct influence of antimicrobials upon virulence mechanisms such as toxin production and adhesion in the bowel, and the exact mechanisms by which the organism causes disease remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602670     DOI: 10.1016/s1286-4579(99)80054-9

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  25 in total

1.  Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus.

Authors:  N J Asha; D Tompkins; M H Wilcox
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 2.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 3.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

Review 4.  Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Gut Microbes       Date:  2013-12-11

Review 5.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  The evolution of acetyl-CoA synthase.

Authors:  P A Lindahl; B Chang
Journal:  Orig Life Evol Biosph       Date:  2001 Aug-Oct       Impact factor: 1.950

Review 7.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

8.  Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues.

Authors:  Emanuela Calabi; Franco Calabi; Alan D Phillips; Neil F Fairweather
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

10.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.